S

Shattuck Labs

D
STTK
USD
0.025
(2.0408%)
Market Closed
5,253.00
Volume
-1.73
EPS
-
Div Yield
-0.675676
P/E
59,659,086.25
Market Cap
Today
2.0408%
1 Week
-1.186%
1 Month
11.607%
6 Months
-88.372%
12 Months
-43.182%
Year To Date
-82.320%
All Time
0%

Title:
Shattuck Labs

Sector:
Healthcare
Industry:
Biotechnology
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Do you need help or have a question?